AC Immune (ACIU)
NASDAQ:ACIU
Want to see ACIU full AI Analyst Report?
ACIU Stock Chart & Stats
$3.01
-$0.09(-3.07%)
At close: 4:00 PM EST
$3.01
-$0.09(-3.07%)
Day’s Range― - ―
52-Week Range$1.65 - $4.00
Previous CloseN/A
Volume13.14K
Average Volume (3M)296.13K
Market Cap
$244.26M
Enterprise Value$175.44M
Total Cash (Recent Filing)$91.52M
Total Debt (Recent Filing)$4.55M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Jul 30, 2026EPS Estimate
0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding101,773,575
10 Day Avg. Volume313,899
30 Day Avg. Volume296,128
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)5.58
Price to Sales (P/S)70.23
P/FCF Ratio-3.74
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue49.10
Enterprise Value/Gross Profit49.10
Enterprise Value/Ebitda-2.58
Forecast
1Y Price Target
$12.00Price Target Upside298.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.34
Revenue Forecast (FY)$31.21M
Bulls Say, Bears Say
Bulls Say
Strategic Pharma Partnerships & Milestone UpsideMaterial milestone triggers and a large Takeda option structure provide durable non-dilutive financing and commercial validation. Big‑pharma alignment increases resources for clinical development, regulatory strategy and potential commercialization, lowering execution risk for late-stage assets.
Amended Lilly Collaboration Expands Funding And Program ScopeThe Lilly amendment supplies immediate non-dilutive cash, validates Morphomer Tau candidates, and secures long-term milestone/royalty upside. It strengthens AC Immune’s funding mix and external development options, improving resilience and increasing the chance of clinical advancement without sole reliance on internal capital.
Broad, Advancing Clinical Pipeline With Multiple Near-term ReadoutsMultiple programs across amyloid, tau, alpha‑synuclein and NDD diagnostics create diversified value pathways. Concurrent readouts and early positive signals (Parkinson’s interim data, TDP‑43 PET) raise probability that at least one program yields a durable technical or partnering success, reducing binary program risk.
Bears Say
Reversal To Heavy Cash BurnThe swing back to deep negative operating and free cash flow signals persistent funding needs tied to the company’s development spending. Over a 2–6 month horizon this structural cash drain makes execution contingent on milestone receipts or financing, increasing dilution risk and potential programme pacing constraints.
Eroded Equity And Large Accumulated LossesSignificant cumulative losses and declining equity reduce the balance‑sheet buffer that absorbs clinical or commercial setbacks. With equity down materially over recent years, the company has less resilience to adverse trial outcomes and more reliance on external capital or partnerships to sustain its development plan.
Volatile, Collaboration-dependent RevenueRevenue largely arises from episodic collaboration payments and grants, making cash inflows lumpy and unpredictable. This structural dependence raises cliff risk if expected milestones or partner payments are delayed or fail, forcing urgent fundraising or program slowdowns that can alter long-term development timelines.
AC Immune SA News
ACIU FAQ
What was AC Immune’s price range in the past 12 months?
AC Immune lowest stock price was $1.65 and its highest was $4.00 in the past 12 months.
What is AC Immune’s market cap?
AC Immune’s market cap is $244.26M.
When is AC Immune’s upcoming earnings report date?
AC Immune’s upcoming earnings report date is Jul 30, 2026 which is in 40 days.
How were AC Immune’s earnings last quarter?
AC Immune released its earnings results on Apr 30, 2026. The company reported -$0.191 earnings per share for the quarter, beating the consensus estimate of -$0.193 by $0.003.
Is AC Immune overvalued?
According to Wall Street analysts AC Immune’s price is currently Undervalued.
Does AC Immune pay dividends?
AC Immune does not currently pay dividends.
What is AC Immune’s EPS estimate?
AC Immune’s EPS estimate is 0.25.
How many shares outstanding does AC Immune have?
AC Immune has 101,773,575 shares outstanding.
What happened to AC Immune’s price movement after its last earnings report?
AC Immune reported an EPS of -$0.191 in its last earnings report, beating expectations of -$0.193. Following the earnings report the stock price went up 3.413%.
Which hedge fund is a major shareholder of AC Immune?
Currently, no hedge funds are holding shares in ACIU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AC Immune SA Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (298.67% Upside)
$12.00 (298.67% Upside)
Blogger Sentiment
Bullish
ACIU Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 739.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $59.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 4.5%
Last 30 Days ▲ 4.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
21.21%
12-Months-Change
Fundamentals
Return on Equity
-123.98%
Trailing 12-Months
Asset Growth
-28.32%
Trailing 12-Months
Company Description
AC Immune
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. Its pipeline features Crenezumab, a humanized, conformation-specific monoclonal antibody currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candidate, which is in Phase II clinical evaluation for AD and has successfully completed a Phase Ib study for Down syndrome. Other key candidates include ACI-35, an anti-Tau vaccine candidate that has finished Phase Ib clinical assessment, and a Tau-positron emission tomography (PET) imaging tracer, also in Phase II development. Furthermore, the company is engaged in the research and development of small molecule inhibitors to prevent Tau aggregation, targeting AD and various NeuroOrphan indications. Early-stage efforts include discovery and preclinical programs for a spectrum of neurodegenerative diseases, encompassing diagnostic agents aimed at TDP-43, alpha-synuclein, and NLRP3. The company maintains strategic partnerships and licensing agreements with key industry players such as Genentech, Inc., Biogen International GmbH, Janssen Pharmaceuticals, Inc., Life Molecular Imaging SA, Eli Lilly and Company, and WuXi Biologics. Founded in 2003, AC Immune S.A. is headquartered in Lausanne, Switzerland.
ACIU Stock 12 Month Forecast
Average Price Target
$12.00
▲(298.67% Upside)
Technical Analysis
Editas Medicine
―
Alector
―
MoonLake Immunotherapeutics
―
Foghorn Therapeutics
―
Vor Biopharma
―
Ownership Overview
4.12% Insiders
0.16% Mutual Funds
19.63% Other Institutional Investors
75.35% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---